Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial
DiscussionThis is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan, Hubei Province, China on 6th February 2020.Trial registrationClinicalTrials.gov: NCT04257656. Registered on 6 February 2020. (Source: Trials)
Source: Trials - May 23, 2020 Category: Research Source Type: clinical trials
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon- β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial
AbstractThe MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon- β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed a s a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The aim of this article is to describe the statistical analysis plan for the MIRACLE trial. The pr...
Source: Trials - January 2, 2020 Category: Research Source Type: clinical trials
A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate (MERS-CoV) Vaccine ChAdOx1 MERS
Condition: Middle East Respiratory Syndrome Coronavirus Intervention: Biological: ChAdOx1 MERS Sponsors: King Abdullah International Medical Research Center; University of Oxford Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 20, 2019 Category: Research Source Type: clinical trials
A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)
Condition: Middle East Respiratory Syndrome Coronavirus Intervention: Biological: ChAdOx1 MERS Sponsors: King Abdullah International Medical Research Center; University of Oxford Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 20, 2019 Category: Research Source Type: clinical trials
